Just Other Articles

There are several solutions to unsecured debt problems in the UK. Many cases though will come to a point where a decision has to be made between an IVA or bankruptcy.

So what are the points t

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

o consider? Is an IVA or a bankruptcy better for the debtor. Well this depends on the debtors circumstances but here are some of the factors that need to de understood and considered.

IVA

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

and bankruptcy timescales differ

An IVA normally lasts for 60 months whereas bankruptcy normally lasts for 12 months. There is a likelihood that payments from a proportion of disposable i

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

come for 3 years need to be paid to the Official Receiver as a result of going bankrupt in the UK under a bankruptcy restriction order (BRO) . This BRO will be put in place by the Official Rec

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

eiver following the bankruptcy order being made by a count or high court judge. So it means that the impact to the debtor in terms of payments from income will last for either 60 months for an

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

IVA or a possible 36 months in bankruptcy.

Position of authority lost / maintained

Bankruptcy has a more far reaching effect on the number of positions of responsibility it can effec

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

. Bankruptcy often leads to a loss of position in many professional or higher positions of both private and public office and also directorship of a company. IVA tends to be more forgiving but

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

importantly doesn't affect the debtors position as a director of a company.

Assets lost / kept

Owning property going into a bankruptcy means that the Official Receiver will own an in

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

terest in that property. Where the property has equity that can be realised then there is a likelihood that the property will be sold by the Official Receiver at some point within 3 years of t

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

e bankruptcy and the proceeds after costs made available to the creditors.

Owning property going into an IVA still requires an interest in that property to be made available for the creditors

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

but is unlikely to lead to the disposal of the asset.

Public bankruptcy / discreet IVA debt solution

Bankruptcy is a very public matter. Bankruptcy notices are posted in the local ne

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

wspapers along with the London Gazette. In contrast an IVA is not advertised in the local press. For this reason an IVA is considered as a discreet solution for dealing with unsecured debt iss

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

es.

Credit availability

IVA and bankruptcy in the UK both limit the opportunity to get further credit in the short and medium term.

Importantly, if a debtor in the UK decides to go b

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ankrupt then they are legally required to inform potential lenders that they are a bankrupt if applying for more than ?500 of credit. There is no legal obligation to inform a potential credito

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

r that you are in an IVA

HP agreements

The vast majority of car leasing and HP agreements have a clause written into the contract that the vehicle must be returned in the event of the

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

debtor entering into bankruptcy. The same is not true for an IVA agreement.

The creditor

Typically, an IVA provides a better return for the creditor than bankruptcy. Whilst both solut

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ions allow a fresh start for the debtor, most creditors will prefer an IVA to bankruptcy as the possibility of some sort of return is higher with the IVA.

Disposable income

Above all,

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

an IVA requires a regular amount of disposable income to be available on a monthly basis. If there is no regular monthly amount of disposable income available and the decision has been narrow

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

d down to an IVA or a bankruptcy then the choice will fall on the side of bankruptcy.

This article provides some insight into the decision between a bankruptcy v. an IVA in the UK. It cannot

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

replace face-to-face advice with a professional. For this reason, do take proper advice from somebody who specialises in the insolvency arena if you are facing issues with your unsecured debts

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justotherarticles.org.ua/article/90861/justotherarticles-Bankruptcy-UK-v-IVA-UK.html">Bankruptcy UK v. IVA UK</a>

BB link (for phorums):
[url=http://www.justotherarticles.org.ua/article/90861/justotherarticles-Bankruptcy-UK-v-IVA-UK.html]Bankruptcy UK v. IVA UK[/url]

Crisis is visibly recognised when the company faces credit squeeze, negative profitability, cash flow problems and collection concerns. However, before the full crisis manifests itself the management of failing companies goes through a four stage of crisis development

Eliminating distractions and eliciting feedback make for a professional and effective presentation. Here are a few tips to accomplish both. A focused and concentrated audience will make your job as a trainer easier and their feedback will help you develop your skills in the future.

If you are a loan officer or mortgage broker on the market for internet mortgage leads, than many things will be of importance to you, including the cost of the lead.

Tags

Links

Just Other Articles - Bankruptcy UK v. IVA UK

Related Articles: